Fast Track Designation is available to drugs that may provide an advantage over current therapies in the treatment of serious conditions. It is designed to speed the development o ...
Fintel reports that on September 30, 2024, Guggenheim initiated coverage of Verastem (NasdaqCM:VSTM) with a Buy ...
13d
HIGHLIGHTS The US FDA has granted Fast Track Designation to Amplia's lead drug narmafotinib in advanced pancreatic cancer Fast Track Designation facilitates the development of investigational drugs an ...
has granted Fast Track Designation to Amplia's Focal Adhesion Kinase inhibitor, narmafotinib, for the treatment of advanced pancreatic cancer. Fast Track Designation is available to drugs that may ...
ERK5 suppression overcomes FAK inhibitor resistance in mutant KRAS-driven non-small cell lung cancer
Focal Adhesion Kinase (FAK) acts as a mediator in sustaining KRAS-driven lung tumors, and although FAK inhibitors are currently undergoing clinical development, clinical data indicated that their ...
It is a small molecule administered through oral route. It acts by targeting focal adhesion kinase (FAK). The drug candidate was also under development for the treatment of triple negative breast ...
They serve as anchoring points for the cells. Every cell has many of these anchoring points, called focal adhesions, which give the cell support like little feet. Integrins have to cooperate with ...
Verastem’s Avutometinib and Defactinib combination therapy targets recurrent LGSOC and is expected to complete its rolling NDA by 2H2024. The company has a diverse pipeline, exploring treatments ...
They serve as anchoring points for the cells. Every cell has many of these anchoring points, called focal adhesions, which give the cell support like little feet. Integrins have to cooperate with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback